The decrease in the antithrombin III activity is thought to result from consumption by ongoing coagulation, degradation by neutrophil elastase, capillary leak syndrome, and impaired synthesis. A retrospective data analysis of patients with sepsis was conducted to investigate the response of antithrombin III activity after supplementation in patients with sepsis, and to determine what factors affect the response of antithrombin III activity.
DIC
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Abstract
The decrease in the antithrombin III activity is thought to result from consumption by ongoing coagulation, degradation by neutrophil elastase, capillary leak syndrome, and impaired synthesis. A retrospective data analysis of patients with sepsis was conducted to investigate the response of antithrombin III activity after supplementation in patients with sepsis, and to determine what factors affect the response of antithrombin III activity.
The study included 42 sepsis, 75 severe sepsis and 65 septic shock patients, who were administrated antithrombin III. Antithrombin III activity, platelet counts, coagulation and fibrinolytic markers were collected before administration and 24 hr after the supplementation.
In the patients with septic shock, the response of antithrombin III activity after supplementation was 0.37 ± 1.21%/IU/kg body weight, which was significantly lower in comparison to those in the patients with sepsis (1.81 ± 1.75; P < 0.001) or severe sepsis (1.36 ± 1.65; P < 0.001). The patients with liver dysfunction had significantly lower DIC = disseminated intravascular coagulation ICU = intensive care unit JAAM = Japanese Association for Acute Medicine SIRS = systemic inflammatory response syndrome SOFA = sequential organ failure assessment 2 response to antithrombin III activity than that of the patients without liver dysfunction (P < 0.0001). A stepwise multiple-linear regression analysis revealed that the severity of sepsis and liver function were independent predictors for the response to antithrombin III activity.
These results suggest that the response to antithrombin III supplementation may be affected by both a systemic inflammation and impaired synthesis in patients with sepsis.
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INTRODUCTION
Sepsis is defined as a systemic inflammatory response syndrome (SIRS) induced by infection, which is frequently associated with disseminated intravascular coagulation (DIC). DIC induces impairments in microcirculation and contributes to later multiple organ dysfunction syndrome (1, 2) . This sequential pathophysiology is frequently complicated with the depletion of antithrombin III activity (1, 2) . The decrease in antithrombin III level has been thought to result from consumption by ongoing coagulation, degradation by neutrophil elastase, capillary leak syndrome, and impaired synthesis (2-7). The level of antithrombin III has been reported to be a good prognostic factor for the prediction of subsequent death (1) .
Recently, several studies showed evidence suggesting the benefit of antithrombin III supplementation therapy for septic patients with low antithrombin III activity (8-12). In the KyberSept trial, patients with severe sepsis received 30,000 IU antithrombin III with a loading dose of 6,000 IU followed by a continuous IV infusion of DIC = disseminated intravascular coagulation ICU = intensive care unit JAAM = Japanese Association for Acute Medicine SIRS = systemic inflammatory response syndrome SOFA = sequential organ failure assessment 
Intervention and Treatment
The clinical indications for using antithrombin III in the ICU 
RESULTS

Patient characteristics
The overall number of patients who were admitted to the ICU during the study period was 2,649. In the present study, antithrombin III was administered a total of 182 times to 42 patients with sepsis, 75 patients with severe sepsis and 65 patients with septic shock. The infection sites of these patients are presented in Table 1 . Table 2 shows the patients characteristics. The initial antithrombin III activity levels and dose of antithrombin III administered to the patients were identical among the three groups. The total input/output balance was not different among the three groups on the day of antithrombin III administration. There were significant differences in the SOFA score, the frequency of DIC, DIC score, and 28-day outcome among the three groups (P < 0.01). The SOFA score was different in each of the severity groups of sepsis (P < 0.05). The frequency of DIC and DIC score in the patients with sepsis were lower than that in the patients with either severe sepsis or septic shock (P < 0.05). The 28-day DIC = disseminated intravascular coagulation ICU = intensive care unit JAAM = Japanese Association for Acute Medicine SIRS = systemic inflammatory response syndrome SOFA = sequential organ failure assessment 10 survival rate in the patients with sepsis was higher than that in the patients with severe sepsis or septic shock (P < 0.01).
The evaluation of the correlation between the severity of sepsis and other variables were as follows: The SOFA score increased in proportion to the severity of sepsis ( = 0.696, P < 0.0001). The JAAM DIC score of the patients significantly increased in proportion to the severity of sepsis ( = 0.232, P = 0.002).
Response to antithrombin III supplementation
The responses of antithrombin III activity after supplementation in the three groups are presented in Fig. 1 . In the patients with septic shock, the response of antithrombin III activity was 0.37 ± 1.21%/IU/kg body weight, which was significantly lower than that of the patients with sepsis or severe sepsis (P < 0.001). In the sepsis and severe sepsis groups, one unit antithrombin III per kg body weight increased antithrombin III activity by 1.81 ± 1.75% and 
DISCUSSION
This study demonstrated that the response to antithrombin III activity after supplementation decreased in proportion to the severity of sepsis and liver dysfunction. The DIC score and the SOFA score also significantly increased in proportion to the severity of sepsis.
The 28-day survival rate in the patients with sepsis was higher than that in the patients with severe sepsis or septic shock.
In patients with sepsis, the decrease in the antithrombin III level is thought to result from: 1) consumption by ongoing coagulation; 2) degradation by neutrophil elastase; 3) capillary leak syndrome; and 4) impaired synthesis (2-7,16).
Sepsis is defined as a SIRS due to infection (13) 
